Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1997 1
2002 1
2004 1
2006 1
2010 2
2012 2
2014 1
2016 1
2018 4
2019 2
2020 3
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

22 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean carnevali l[au] (121 results)?
Myc Depletion Induces a Pluripotent Dormant State Mimicking Diapause.
Scognamiglio R, Cabezas-Wallscheid N, Thier MC, Altamura S, Reyes A, Prendergast ÁM, Baumgärtner D, Carnevalli LS, Atzberger A, Haas S, von Paleske L, Boroviak T, Wörsdörfer P, Essers MA, Kloz U, Eisenman RN, Edenhofer F, Bertone P, Huber W, van der Hoeven F, Smith A, Trumpp A. Scognamiglio R, et al. Among authors: carnevalli ls. Cell. 2016 Feb 11;164(4):668-80. doi: 10.1016/j.cell.2015.12.033. Cell. 2016. PMID: 26871632 Free PMC article.
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1.
Proia TA, Singh M, Woessner R, Carnevalli L, Bommakanti G, Magiera L, Srinivasan S, Grosskurth S, Collins M, Womack C, Griffin M, Ye M, Cantin S, Russell D, Xie M, Hughes A, Deng N, Mele DA, Fawell S, Barry S, Reimer C, Barrett JC, McCoon P. Proia TA, et al. Among authors: carnevalli l. Clin Cancer Res. 2020 Dec 1;26(23):6335-6349. doi: 10.1158/1078-0432.CCR-20-1066. Epub 2020 Sep 17. Clin Cancer Res. 2020. PMID: 32943458
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.
Michaloglou C, Crafter C, Siersbaek R, Delpuech O, Curwen JO, Carnevalli LS, Staniszewska AD, Polanska UM, Cheraghchi-Bashi A, Lawson M, Chernukhin I, McEwen R, Carroll JS, Cosulich SC. Michaloglou C, et al. Among authors: carnevalli ls. Mol Cancer Ther. 2018 May;17(5):908-920. doi: 10.1158/1535-7163.MCT-17-0537. Epub 2018 Feb 26. Mol Cancer Ther. 2018. PMID: 29483206 Free PMC article.
Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery.
Taylor MA, Hughes AM, Walton J, Coenen-Stass AML, Magiera L, Mooney L, Bell S, Staniszewska AD, Sandin LC, Barry ST, Watkins A, Carnevalli LS, Hardaker EL. Taylor MA, et al. Among authors: carnevalli ls. J Immunother Cancer. 2019 Nov 28;7(1):328. doi: 10.1186/s40425-019-0794-7. J Immunother Cancer. 2019. PMID: 31779705 Free PMC article.
Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma.
Floc'h N, Ashton S, Ferguson D, Taylor P, Carnevalli LS, Hughes AM, Harris E, Hattersley M, Wen S, Curtis NJ, Pilling JE, Young LA, Maratea K, Pease EJ, Barry ST. Floc'h N, et al. Among authors: carnevalli ls. Mol Cancer Ther. 2019 May;18(5):909-919. doi: 10.1158/1535-7163.MCT-18-0577. Epub 2019 Mar 14. Mol Cancer Ther. 2019. PMID: 30872381 Free article.
Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer.
Avivar-Valderas A, McEwen R, Taheri-Ghahfarokhi A, Carnevalli LS, Hardaker EL, Maresca M, Hudson K, Harrington EA, Cruzalegui F. Avivar-Valderas A, et al. Among authors: carnevalli ls. Oncotarget. 2018 Apr 20;9(30):21444-21458. doi: 10.18632/oncotarget.25118. eCollection 2018 Apr 20. Oncotarget. 2018. PMID: 29765551 Free PMC article.
22 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page